KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Shares Outstanding (Weighted Average): 2013-2025

Historic Shares Outstanding (Weighted Average) for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to $89.1 million.

  • Travere Therapeutics' Shares Outstanding (Weighted Average) rose 16.53% to $89.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.1 million, marking a year-over-year increase of 16.53%. This contributed to the annual value of $78.0 million for FY2024, which is 3.86% up from last year.
  • Per Travere Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $89.1 million for Q3 2025, which was up 0.38% from $88.8 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Shares Outstanding (Weighted Average) peaked at $89.1 million during Q3 2025, and registered a low of $60.2 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $78.5 million, with a median of $76.1 million in 2024.
  • Data for Travere Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY soared of 40.09% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Travere Therapeutics' Shares Outstanding (Weighted Average) stood at $61.2 million in 2021, then grew by 4.81% to $64.2 million in 2022, then grew by 17.10% to $75.1 million in 2023, then grew by 3.86% to $78.0 million in 2024, then increased by 16.53% to $89.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $89.1 million for Q3 2025, versus $88.8 million for Q2 2025 and $88.7 million for Q1 2025.